Advancing Innovative Therapies Across Neurology and Neuropsychiatry to Address Critical Unmet Needs
THERAPEUTIC PIPELINE
| Target | Indication* | |
|---|---|---|
| D2/D3 Partial Agonist, 5-HT2A Antagonist |
Schizophrenia |
|
| GABAAR PAM | Tinnitus |
|
| Uncompetitive GAT-1 Inhibitor | Focal Epilepsy | |
| PDE9 Inhibitor | Reversible encephalopathies | |
| Undisclosed | Undisclosed |
TRTL-107
D2/D3 Partial Agonist, 5-HT2A Antagonist
Schizophrenia
TRTL-913
GABAAR PAM
Tinnitus
TRTL-729
Uncompetitive GAT-1 Inhibitor
Focal Epilepsy
TRTL-118
PDE9 Inhibitor
Reversible
encephalopathies
Discovery
Undisclosed
Undisclosed
| DISCOVERY | PRECLINICAL | PHASE I | PHASE II | PHASE III | PARTNER | |
|---|---|---|---|---|---|---|
|
TRTL-107 |
|
|
||||
|
TRTL-913 |
|
|
||||
|
TRTL-729 |
|
|
||||
|
TRTL-118 |
|
|
||||
|
Discovery |
|
|||||
*While development is currently focused on lead indications, we are actively evaluating additional patient populations to expand each asset’s potential.